Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials

British Journal of Dermatology

Volumn 149, Issue 2, 2003, Pages 323-331

  McKenna, Stephen P ^a   Cook, S A ^a   Whalley, D ^a   Doward, L C ^a   Richards, H L ^b   Griffiths, C E M ^b   Van Assche, D ^c  

^a GALEN RESEARCH   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Psoriasis; PSORIQoL; Quality of life; Questionnaire

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EMOTIONAL STABILITY; FEMALE; HUMAN; INFORMED CONSENT; INTERVIEW; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NETHERLANDS; POSTAL MAIL; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RATING SCALE; REPRODUCIBILITY; SAMPLING; SELF EVALUATION; SOCIALIZATION; UNITED KINGDOM; VALIDATION PROCESS;

ADULT; AGED; ENGLAND; FEMALE; FOCUS GROUPS; HEALTH SERVICES RESEARCH; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PSORIASIS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0042413555     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05492.x     Document Type: Article

References (37)

1. Gawkrodger DJ on behalf of the Therapy Guidelines and Audit Subcommittee of the British Association of Dermatologists. Current management of psoriasis. J Dermatol Treat 1997; 8: 27-55.
2. Fried RG, Friedman S, Paradis C. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995; 34: 101-5.
3. Hughes JE, Barraclough M, Hamblin LG et al. Psychiatric symptoms in dermatology patients. Br J Psychiatry 1983; 143: 51-4.
4. Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1985; 20: 425-9.
5. Fortune DG, Main CJ, O'Sullivan TM et al. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137: 755-60.
6. Ramsey B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988; 118: 195-201.
7. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-44.
8. Wahl AK, Gjengedal E, Hanestad BR. The bodily suffering of living with severe psoriasis: in-depth interviews with 22 hospitalized patients with psoriasis. Qual Health Res 2002; 12: 250-61.
9. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
10. Nichol MB, Margolis JE, Lippa E et al. The application of multiple quality of life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996; 10: 644-53.
11. McKenna SP, Whalley D, Doward LC. Which outcomes are important in schizophrenia trials? Int J Methods Psychiatr Res 2000; 9 (Suppl.): S58-67.
12. Finlay AY, Kelly SE. Psoriasis - an index of disability. Clin Exp Dermatol 1987; 12: 8-11.
13. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
14. Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol (Stockh) 1995; 75: 240-3.
15. Chren MM, Lasek RJ, Quinn LM et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-13.
16. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales - a measure of the impact of skin diseases. Br J Dermatol 1997; 136: 202-6.
17. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy 1992; 22: 307-19.
18. Gill TM, Feinstein AR. A critical appraisal of the quality of quality of life measurements. JAMA 1994; 272: 619-25.
19. Holmes SJ, McKenna SP, Doward LC, Shalet SM. Development of a questionnaire to assess the quality of life of adults with growth hormone deficiency. Endocrinol Metab 1995; 2: 63-9.
20. Wagner TH, Patrick DL, McKenna SP, Froese MA. Cross-cultural development of a quality of life measure for men with erection difficulties. Qual Life Res 1996; 5: 443-9.
21. de Jong Z, van der Heijde D, McKenna SP, Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 1997; 36: 878-83.
22. McKenna SP, Doward LC, Mackenzie Davey K. The development and psychometric properties of the MSQOL; a migraine-specific quality-of-life instrument. Clin Drug Invest 1998; 15: 413-23.
23. Doward LC, McKenna SP, Kohlmann T et al. The international development of the RGHQoL: a quality of life measure for recurrent genital herpes. Qual Life Res 1998; 7: 143-53.
24. Whalley D, McKenna SP, Dewar AL et al. Quality of life in adults with atopic dermatitis - the international development of the QoLIAD. Qual Life Res 2000; 9: 322.
25. Whalley D, McKenna SP, Dewar AL et al. International development of a measure to assess quality of life in childhood atopic dermatitis - the PIQOL-AD. Qual Life Res 2000; 9: 302.
26. Hunt SM, McKenna SP. A British adaptation of the General Well-Being Index: a new tool for clinical research. Br J Med Econ 1992; 2: 49-60.
27. Andrich D. Rasch Models for Measurement. London: Sage Publications, 1988.
28. Weiner EA, Stewart BJ. Assessing Individuals. Boston: Little, Brown, 1984.
29. Nunally JC Jr. Psychometric Theory, 2nd edn. New York: McGraw-Hill, 1978.
30. Berzon R, Hays KD, Shumaker SA. International use, application and performance of health-related quality of life instruments. Qual Life Res 1993; 2: 367-8.
31. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-96.
32. Hunt SM. The problem of quality of life. Qual Life Res 1997; 6: 205-12.
33. Tuynman-Qua H, de Jonghe F, McKenna SP. Quality of Life in Depression Scale (QLDS). Development, reliability, validity, responsiveness and application. Eur Psychiatry 1997; 12: 199-202.
34. McKenna SP, Doward LC, Alonso J et al. The QoL-AGHDA, an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999; 8: 373-83.
35. Patel R, Tyring S, Strand A et al. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999; 75: 398-402.
36. Whalley D, Huels J, McKenna SP, van Assche D. The benefit of pimecrolimus (Elidel®, SDZ ASM 981) on quality of life in the treatment of mild-to-moderate paediatric atopic eczema. Pediatrics 2002; 110: 1133-6.
37. Krueger GG, Feldman SR, Camisa C et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-5.